Envestnet Asset Management Inc. Has $218.28 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Envestnet Asset Management Inc. raised its position in Kenvue Inc. (NYSE:KVUE) by 79.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 10,224,056 shares of the company’s stock after acquiring an additional 4,523,918 shares during the period. Envestnet Asset Management Inc.’s holdings in Kenvue were worth $218,284,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Grove Bank & Trust raised its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. lifted its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE opened at $22.33 on Monday. The firm has a market cap of $42.68 billion, a P/E ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The business’s fifty day moving average is $22.59 and its 200-day moving average is $22.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Barclays raised their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.